The benefits of wearable continuous glucose monitors extend far beyond insulin users, according to a new study published this week: people with type 2 diabetes who do not take insulin saw meaningful improvements in blood sugar control after six months of using the devices, researchers reported in The New England Journal of Medicine. The finding, highlighted by Reuters on October 16, 2026, could eventually reshape how doctors manage one of the world's most common chronic conditions.
Illustration: An AI-generated depiction of a coin-sized Dexcom G7 wearable glucose monitor on a patient's upper arm, paired with a smartphone showing glucose data. This is an illustration, not a real photo.
What Happened
In a six-month trial sponsored by device maker Dexcom, 283 adults with type 2 diabetes who were not using insulin were assigned either to wear the Dexcom G7 — a coin-sized plastic disc worn on the upper arm — or to continue with routine care, according to Reuters' reporting. The results were striking: average hemoglobin A1c, the standard measure of blood sugar over time, fell from 8.8% to 7.2% in the monitoring group, compared with a decline from 8.7% to 8.0% in the routine-care group. After adjusting for individual risk factors, device users achieved a reduction in HbA1c nearly one percentage point greater than those receiving standard treatment.
Participants using the wearable also spent roughly five additional hours per day within the target glucose range of 70 to 180 milligrams per deciliter compared with the routine-care group. The benefit held across age, sex, race and ethnicity, body mass index, income, education, health insurance status and use of glucose-lowering medications — suggesting the effect is not limited to any narrow subgroup. When the study ended, 97% of participants were still using the monitors, most on a daily basis, the researchers noted.
The trial also flagged other notable health developments in its roundup, including a positive trial of a Johnson & Johnson pill for ulcerative colitis and a new discovery about ovarian health after menopause — underscoring how active medical research remains across specialties.
Background
Continuous glucose monitors were developed primarily for people who depend on insulin — those with type 1 diabetes and the subset of type 2 patients on insulin therapy — because real-time readings are critical for avoiding dangerous lows. Until now, clinical recommendations have generally reserved the devices for insulin users, and insurers in many countries cover them only for that group. Hundreds of millions of people worldwide live with diabetes, the vast majority with type 2, and most of them manage the condition without insulin, relying instead on diet, exercise and oral medications.
The HbA1c scale is a familiar yardstick to anyone managing diabetes: values below 7% are the typical target for most adults, and each percentage point of sustained reduction is associated with substantially lower risks of complications such as eye, kidney and nerve damage over the long term. That context is what makes a near-one-point advantage over routine care — in patients who had previously been considered poor candidates for the technology — clinically significant in the eyes of diabetes specialists.
Study leader Dr. Roy Beck of the Jaeb Center for Health Research in Tampa, Florida, said the consistency of the benefit across a broad range of people and treatment regimens supports considering a continuous glucose monitor "much earlier in type 2 diabetes management, before insulin is needed," according to a statement cited by Reuters. It is worth noting that the trial was sponsored by Dexcom itself, which has a commercial interest in expanding the market for its devices — a detail regulators and insurers will weigh alongside the data.
Illustration: An AI-generated depiction of a blood sugar trend chart with a doctor reviewing glucose data, representing the new diabetes study. This is an illustration, not a real photo.
Why It Matters
The most immediate implication is a potential shift in treatment guidelines. If major diabetes associations begin recommending continuous glucose monitoring for non-insulin type 2 patients, demand for the devices — and pressure on insurers to cover them — would grow sharply. For patients, the attraction is intuitive: seeing real-time feedback on how meals, activity and sleep move the needle can change behavior in ways a quarterly lab test cannot.
There is also a safety dimension that deserves attention. The study suggests benefits even in people who are not taking insulin and therefore face little risk of dangerous lows, but continuous monitoring still generates vast streams of data that require interpretation. Clinicians will need efficient ways to review that information without being overwhelmed — a workflow problem health systems are only beginning to solve.
Cost and access remain the central tension. Wearable monitors are far more expensive than the fingerstick meters most type 2 patients use today, and coverage is uneven even for insulin users in some countries. Whether health systems will pay for earlier, broader use depends on cost-effectiveness analyses that weigh the device price against avoided complications — analyses that typically take years to complete.
What Happens Next
- Guideline reviews: Diabetes associations will now weigh whether to extend continuous glucose monitor recommendations beyond insulin users, a process that usually unfolds over months or years.
- Insurance decisions: Payers will scrutinize the industry-sponsored data and likely commission independent cost-effectiveness reviews before expanding coverage.
- Longer-term follow-up: Six months of improved numbers is encouraging, but researchers will want to see whether the benefits persist over years and translate into fewer complications.
- Broader research: With positive signals also emerging in ulcerative colitis and women's health, October has been a busy month for trials that could change standard care.
Sponsored: explore today's featured sponsored offers
Frequently Asked Questions
Who was included in the Dexcom G7 study?
The trial enrolled 283 adults with type 2 diabetes who were not using insulin. Participants were assigned either to wear a Dexcom G7 continuous glucose monitor or to continue with routine care for six months.
How much did blood sugar improve?
Average HbA1c fell from 8.8% to 7.2% in the monitoring group versus 8.7% to 8.0% in the routine-care group — a difference of nearly one percentage point after adjusting for individual risk factors. Device users also spent about five more hours per day in the target glucose range.
Does this mean every type 2 patient should get a monitor?
Not yet. Guidelines have not changed, and the trial was sponsored by the device manufacturer. Diabetes associations and insurers will review the evidence before extending recommendations to non-insulin users.
Are there downsides to wider use?
Cost is the main one: continuous monitors are far more expensive than fingerstick meters. Doctors also face the practical challenge of reviewing large volumes of glucose data for many more patients.
What did the study find about long-term effects?
The trial measured six months of blood sugar control, not long-term complications. Whether sustained monitor use reduces eye, kidney or nerve damage over years is still an open question that future research will need to answer.
Illustration: An AI-generated depiction of a person checking health data on a phone at home, symbolizing how wearable devices fit into daily diabetes care. This is an illustration, not a real photo.
Sources
- Reuters — "Glucose monitoring devices for type 2 diabetes benefit even those not on insulin" (October 16, 2026)
- The New England Journal of Medicine — Dexcom G7 trial results, led by Dr. Roy Beck, Jaeb Center for Health Research (reported October 2026)
Comments
Post a Comment